Patient-reported tolerance in treatments approved in neuroendocrine tumors: A national survey from the French Group of Endocrine Tumors.

•Two-hundred-forty-two treatments used in neuroendocrine tumors have been evaluated by 54 patients.•Patients had the best perceived tolerance for somatostatin analogs and peptide receptor radionuclide therapy.•Patients had a better perceived tolerance for oral chemotherapy than for intravenous chemotherapy.•The patient's preference may help physicians to sequence the therapeutic strategy.